Abstract
Protein tyrosine kinases (PTK), discovered in the 1970s, have been considered master regulators of biological processes with high clinical significance as targets for human diseases. Their actions are countered by protein tyrosine phosphatases (PTP), enzymes yet underrepresented as drug targets because of the high homology of their catalytic domains and high charge of their catalytic pocket. This scenario is still worse for some PTP subclasses, for example, for the atypical dual-specificity phosphatases (ADUSPs), whose biological functions are not even completely known. In this sense, the present work focuses on the dual-specificity phosphatase 3 (DUSP3), also known as VH1-related phosphatase (VHR), an uncommon regulator of mitogen-activated protein kinase (MAPK) phosphorylation. DUSP3 expression and activities are suggestive of a tumor suppressor or tumor-promoting enzyme in different types of human cancers. Furthermore, DUSP3 has other biological functions involving immune response mediation, thrombosis, hemostasis, angiogenesis, and genomic stability that occur through either MAPK-dependent or MAPK-independent mechanisms. This broad spectrum of actions is likely due to the large substrate diversity and molecular mechanisms that are still under scrutiny. The growing advances in characterizing new DUSP3 substrates will allow the development of pharmacological inhibitors relevant for possible future clinical trials. This review covers all aspects of DUSP3, since its gene cloning and crystallographic structure resolution, in addition to its classical and novel substrates and the biological processes involved, followed by an update of what is currently known about the DUSP3/VHR-inhibiting compounds that might be considered potential drugs to treat human diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2005) Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91:145–151
Alonso A, Saxena M, Williams S, Mustelin T (2001) Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation. J Biol Chem 276:4766–4771
Alonso A, Rahmouni S, Williams S, van Stipdonk M, Jaroszewski L, Godzik A, Abraham RT, Schoenberger SP, Mustelin T (2003) Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol 4:44–48
Alonso A, Narisawa S, Bogetz J, Tautz L, Hadzic R, Huynh H, Williams S, Gjorloff-Wingren A, Bremer MC, Holsinger LJ, Millan JL, Mustelin T (2004a) VHY, a novel myristoylated testis-restricted dual specificity protein phosphatase related to VHX. J Biol Chem 279:32586–32591
Alonso A, Rojas A, Godzik A, Mustelin T (2004b) The dual-specific protein tyrosine phosphatase family. In: Arino J, Alexander DR (eds) Protein phosphatases, vol 5. Springer, Berlin, pp 333–358
Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004c) Protein tyrosine phosphatases in the human genome. Cell 117:699–711
Amand M, Erpicum C, Bajou K, Cerignoli F, Blacher S, Martin M, Dequiedt F, Drion P, Singh P, Zurashvili T, Vandereyken M, Musumeci L, Mustelin T, Moutschen M, Gilles C, Noel A, Rahmouni S (2014) DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Mol Cancer 13:108
Arabaci G, Yi T, Fu H, Porter ME, Beebe KD, Pei D (2002) Alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-activity relationship. Bioorg Med Chem Lett 12:3047–3050
Arimura Y, Yagi J (2010) Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Sci Signal 3:rs1
Arnoldussen YJ, Saatcioglu F (2009) Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol 309:1–7
Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F (2008) The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res 68:9255–9264
Bae EY, Oh H, Oh WK, Kim MS, Kim BS, Kim BY, Sohn CB, Osada H, Ahn JS (2004) A new VHR dual-specificity protein tyrosine phosphatase inhibitor from Dendrobium moniliforme. Planta Med 70:869–870
Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981–1989
Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812–821
Barford D, Flint AJ, Tonks NK (1994) Crystal structure of human protein tyrosine phosphatase 1B. Science 263:1397–1404
Bayón Y, Alonso A (2010) Atypical DUSPs: 19 phosphatases in search of a role, vol 661. Transworld Research Network, Kerala, pp 185–208
Bennardo N, Cheng A, Huang N, Stark JM (2008) Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4:e1000110
Bermudez O, Pages G, Gimond C (2010) The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299:C189–C202
Carneiro VM, Trivella DB, Scorsato V, Beraldo VL, Dias MP, Sobreira TJ, Aparicio R, Pilli RA (2015) Is RK-682 a promiscuous enzyme inhibitor? Synthesis and in vitro evaluation of protein tyrosine phosphatase inhibition of racemic RK-682 and analogues. Eur J Med Chem 97:42–54
Cerignoli F, Rahmouni S, Ronai Z, Mustelin T (2006) Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle 5:2210–2215
Cha H, Hancock C, Dangi S, Maiguel D, Carrier F, Shapiro P (2004) Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies. Biochem J 378:857–865
Chau AS, Shibuya EK (1999) Inactivation of p42 mitogen-activated protein kinase is required for exit from M-phase after cyclin destruction. J Biol Chem 274:32085–32090
Chen YR, Chou HC, Yang CH, Chen HY, Liu YW, Lin TY, Yeh CL, Chao WT, Tsou HH, Chuang HC, Tan TH (2017) Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration. Oncogene 36:6509–6517
Cho SSL, Han J, James SJ, Png CW, Weerasooriya M, Alonso S, Zhang Y (2017) Dual-specificity phosphatase 12 targets p38 MAP kinase to regulate macrophage response to intracellular bacterial infection. Front Immunol 8:1259–1269
Christian KJ, Lang MA, Raffalli-Mathieu F (2008) Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment. Mol Pharmacol 73:1558–1567
Chung HS, Wang SB, Venkatraman V, Murray CI, Van Eyk JE (2013) Cysteine oxidative posttranslational modifications: emerging regulation in the cardiovascular system. Circ Res 112:382–392
Daniely Y, Dimitrova DD, Borowiec JA (2002) Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. Mol Cell Biol 22:6014–6022
Denu JM, Dixon JE (1995) A catalytic mechanism for the dual-specific phosphatases. Proc Natl Acad Sci U S A 92:5910–5914
Denu JM, Dixon JE (1998) Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr Opin Chem Biol 2:633–641
ElShamy WM, Livingston DM (2004) Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol 6:954–967
Engedal N, Korkmaz CG, Saatcioglu F (2002) C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 21:1017–1027
Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR (2006) Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 23:561–574
Farooq A, Zhou MM (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769–779
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45
Foley EA, Kapoor TM (2013) Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore. Nat Rev Mol Cell Biol 14:25–37
Forti FL (2015) Combined experimental and bioinformatics analysis for the prediction and identification of VHR/DUSP3 nuclear targets related to DNA damage and repair. Integr Biol (Camb) 7:73–89
Goldstein M, Derheimer FA, Tait-Mulder J, Kastan MB (2013) Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair. Proc Natl Acad Sci U S A 110:16874–16879
Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6:493–505
Hamaguchi T, Sudo T, Osada H (1995) RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett 372:54–58
Hamaguchi T, Masuda A, Morino T, Osada H (1997) Stevastelins, a novel group of immunosuppressants, inhibit dual-specificity protein phosphatases. Chem Biol 4:279–286
Hao L, ElShamy WM (2007) BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. Int J Cancer 121:39–46
He R, Zeng LF, He Y, Zhang S, Zhang ZY (2013) Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 280:731–750
Hendriks WJ, Elson A, Harroch S, Pulido R, Stoker A, den Hertog J (2013) Protein tyrosine phosphatases in health and disease. FEBS J 280:708–730
Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, Tautz L, Boniver J, Mustelin T, Rahmouni S (2008) Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 8:147
Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380
Hirai G, Tsuchiya A, Koyama Y, Otani Y, Oonuma K, Dodo K, Simizu S, Osada H, Sodeoka M (2011) Development of a Vaccinia H1-related (VHR) phosphatase inhibitor with a nonacidic phosphate-mimicking core structure. ChemMedChem 6:617–622
Hoyt R, Zhu W, Cerignoli F, Alonso A, Mustelin T, David M (2007) Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol 179:3402–3406
Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177–184
Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184
Ishibashi T, Bottaro DP, Chan A, Miki T, Aaronson SA (1992) Expression cloning of a human dual-specificity phosphatase. Proc Natl Acad Sci U S A 89:12170–12174
Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6:391–403
Jeong DG, Cho YH, Yoon TS, Kim JH, Son JH, Ryu SE, Kim SJ (2006) Structure of human DSP18, a member of the dual-specificity protein tyrosine phosphatase family. Acta Crystallogr D Biol Crystallogr 62:582–588
Kang TH, Kim KT (2006) Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. Nat Cell Biol 8:863–869
Kim JH, Cho H, Ryu SE, Choi MU (2000) Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2+ ion. Arch Biochem Biophys 382:72–80
Koike A, Nishikawa H, Wu W, Okada Y, Venkitaraman AR, Ohta T (2010) Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. Cancer Res 70:6746–6756
Kondoh K, Nishida E (2007) Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773:1227–1237
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, Laiho M (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5:465–475
Lang R, Hammer M, Mages J (2006) DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 177:7497–7504
Lawan A, Al-Harthi S, Cadalbert L, McCluskey AG, Shweash M, Grassia G, Grant A, Boyd M, Currie S, Plevin R (2011) Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem 286:12933–12943
Lazo JS, Nunes R, Skoko JJ, Queiroz de Oliveira PE, Vogt A, Wipf P (2006) Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorg Med Chem 14:5643–5650
Lee C, Smith BA, Bandyopadhyay K, Gjerset RA (2005a) DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 65:9834–9842
Lee SY, Park JH, Kim S, Park EJ, Yun Y, Kwon J (2005b) A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J 388:7–15
Levenson RM, Blackshear PJ (1989) Insulin-stimulated protein tyrosine phosphorylation in intact cells evaluated by giant two-dimensional gel electrophoresis. J Biol Chem 264:19984–19993
Liljebris C, Baranczewski P, Bjorkstrand E, Bystrom S, Lundgren B, Tjernberg A, Warolen M, James SR (2004) Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione. J Pharmacol Exp Ther 309:711–719
Lim KH, Park JJ, Gu BH, Kim JO, Park SG, Baek KH (2015) HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response. Sci Rep 5:12793
Lin CY, Tan BC, Liu H, Shih CJ, Chien KY, Lin CL, Yung BY (2010) Dephosphorylation of nucleophosmin by PP1beta facilitates pRB binding and consequent E2F1-dependent DNA repair. Mol Biol Cell 21:4409–4417
Lorenzo PI, Saatcioglu F (2008) Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 10:418–428
Mandl M, Slack DN, Keyse SM (2005) Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 25:1830–1845
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934
Matta H, Surabhi RM, Zhao J, Punj V, Sun Q, Schamus S, Mazzacurati L, Chaudhary PM (2007) Induction of spindle cell morphology in human vascular endothelial cells by human herpesvirus 8-encoded viral FLICE inhibitory protein K13. Oncogene 26:1656–1660
Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED (2007) Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 99:60–67
Miranda GA, Chokler I, Aguilera RJ (1995) The murine nucleolin protein is an inducible DNA and ATP binding protein which is readily detected in nuclear extracts of lipopolysaccharide-treated splenocytes. Exp Cell Res 217:294–308
Mitsui H, Kiecker F, Shemer A, Cannizzaro MV, Wang CQF, Gulati N, Ohmatsu H, Shah KR, Gilleaudeau P, Sullivan-Whalen M, Cueto I, McNutt NS, Suarez-Farinas M, Krueger JG (2016) Discrimination of dysplastic nevi from common melanocytic nevi by cellular and molecular criteria. J Invest Dermatol 136:2030–2040
Mustelin T (2007) A brief introduction to the protein phosphatase families. In: Moorhead G (ed) Protein phosphatase protocols, vol 365. Springer, Totowa, pp 9–122
Musumeci L, Kuijpers MJ, Gilio K, Hego A, Theatre E, Maurissen L, Vandereyken M, Diogo CV, Lecut C, Guilmain W, Bobkova EV, Eble JA, Dahl R, Drion P, Rascon J, Mostofi Y, Yuan H, Sergienko E, Chung TD, Thiry M, Senis Y, Moutschen M, Mustelin T, Lancellotti P, Heemskerk JW, Tautz L, Oury C, Rahmouni S (2014) Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 131:656–668
Nakuci E, Mahner S, Direnzo J, ElShamy WM (2006) BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res 312:3120–3131
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15
Nunes-Xavier C, Roma-Mateo C, Rios P, Tarrega C, Cejudo-Marin R, Tabernero L, Pulido R (2011) Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anti Cancer Agents Med Chem 11:109–132
Olson MO, Dundr M, Szebeni A (2000) The nucleolus: an old factory with unexpected capabilities. Trends Cell Biol 10:189–196
Panico K, Forti FL (2013) Proteomic, cellular, and network analyses reveal new DUSP3 interactions with nucleolar proteins in HeLa cells. J Proteome Res 12:5851–5866
Park J, Fu H, Pei D (2004) Peptidyl aldehydes as slow-binding inhibitors of dual-specificity phosphatases. Bioorg Med Chem Lett 14:685–687
Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ (2008) Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening. ChemMedChem 3:877–880
Park S-J, Song M-A, Cho S-Y (2009) Regulation of vaccinia H1-related (VHR) phosphatase activity by NSC-87877. Bull Kor Chem Soc 30:3098–3100
Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489
Pfender S, Kuznetsov V, Pasternak M, Tischer T, Santhanam B, Schuh M (2015) Live imaging RNAi screen reveals genes essential for meiosis in mammalian oocytes. Nature 524:239–242
Pinol-Roma S (1999) Association of nonribosomal nucleolar proteins in ribonucleoprotein complexes during interphase and mitosis. Mol Biol Cell 10:77–90
Pulido R, Hooft van Huijsduijnen R (2008) Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J 275:848–866
Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, Louis-dit-Sully C, Moutschen M, Jiang W, Mustelin T (2006) Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 8:524–531
Roberts EC, Shapiro PS, Nahreini TS, Pages G, Pouyssegur J, Ahn NG (2002) Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. Mol Cell Biol 22:7226–7241
Salojin K, Oravecz T (2007) Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes. J Leukoc Biol 81:860–869
Schwertassek U, Buckley DA, Xu CF, Lindsay AJ, McCaffrey MW, Neubert TA, Tonks NK (2010) Myristoylation of the dual-specificity phosphatase c-JUN N-terminal kinase (JNK) stimulatory phosphatase 1 is necessary for its activation of JNK signaling and apoptosis. FEBS J 277:2463–2473
Shi Y (2007) Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8:829–833
Shi Z, Tabassum S, Jiang W, Zhang J, Mathur S, Wu J, Shi Y (2007) Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects. Chembiochem 8:2092–2099
Shinohara M, Mikhailov AV, Aguirre-Ghiso JA, Rieder CL (2006) Extracellular signal-regulated kinase 1/2 activity is not required in mammalian cells during late G2 for timely entry into or exit from mitosis. Mol Biol Cell 17:5227–5240
Sicinski P, Weinberg RA (1997) A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 2:335–342
Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA (1995) Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621–630
Singh P, Dejager L, Amand M, Theatre E, Vandereyken M, Zurashvili T, Singh M, Mack M, Timmermans S, Musumeci L, Dejardin E, Mustelin T, Van Ginderachter JA, Moutschen M, Oury C, Libert C, Rahmouni S (2015) DUSP3 genetic deletion confers M2-like macrophage-dependent tolerance to septic shock. J Immunol 194:4951–4962
Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J 13:1911–1922
Stanford SM, Bottini N (2017) Targeting tyrosine phosphatases: time to end the stigma. Trends Pharmacol Sci 38:524–540
Stein GH, Drullinger LF, Robetorye RS, Pereira-Smith OM, Smith JR (1991) Senescent cells fail to express cdc2, cycA, and cycB in response to mitogen stimulation. Proc Natl Acad Sci U S A 88:11012–11016
Takagi M, Absalon MJ, McLure KG, Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123:49–63
Tambe MB, Narvi E, Kallio M (2016) Reduced levels of Dusp3/Vhr phosphatase impair normal spindle bipolarity in an Erk1/2 activity-dependent manner. FEBS Lett 590:2757–2767
Tamura S, Brown TA, Whipple JH, Fujita-Yamaguchi Y, Dubler RE, Cheng K, Larner J (1984) A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem 259:6650–6658
Tanzola MB, Kersh GJ (2006) The dual specificity phosphatase transcriptome of the murine thymus. Mol Immunol 43:754–762
Tautz L, Senis YA, Oury C, Rahmouni S (2015) Perspective: tyrosine phosphatases as novel targets for antiplatelet therapy. Bioorg Med Chem 23:2786–2797
Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426
Todd JL, Tanner KG, Denu JM (1999) Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J Biol Chem 274:13271–13280
Tonks NK (2013) Protein tyrosine phosphatases – from housekeeping enzymes to master regulators of signal transduction. FEBS J 280:346–378
Torres TE, Russo LC, Santos A, Marques GR, Magalhaes YT, Tabassum S, Forti FL (2017) Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways. Biochim Biophys Acta 1861:1879–1894
Ueda K, Usui T, Nakayama H, Ueki M, Takio K, Ubukata M, Osada H (2002) 4-isoavenaciolide covalently binds and inhibits VHR, a dual-specificity phosphatase. FEBS Lett 525:48–52
Vandereyken M, Jacques S, Van Overmeire E, Amand M, Rocks N, Delierneux C, Singh P, Singh M, Ghuysen C, Wathieu C, Zurashvili T, Sounni NE, Moutschen M, Gilles C, Oury C, Cataldo D, Van Ginderachter JA, Rahmouni S (2017a) Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. PLoS One 12:e0185786
Vandereyken MM, Singh P, Wathieu CP, Jacques S, Zurashvilli T, Dejager L, Amand M, Musumeci L, Singh M, Moutschen MP, Libert CRF, Rahmouni S (2017b) Dual-specificity phosphatase 3 deletion protects female, but not male, mice from endotoxemia-induced and polymicrobial-induced septic shock. J Immunol 199:2515–2527
Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T (2008) Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 26:29–55
Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849
Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG (2013) KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 123:5231–5246
Wang JY, Yeh CL, Chou HC, Yang CH, Fu YN, Chen YT, Cheng HW, Huang CY, Liu HP, Huang SF, Chen YR (2011) Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer. J Biol Chem 286:10177–10184
Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080 discussion 3080
Willard FS, Crouch MF (2001) MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit. Cell Signal 13:653–664
Wu MH, Chang JH, Chou CC, Yung BY (2002a) Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int J Cancer 97:297–305
Wu MH, Chang JH, Yung BY (2002b) Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 23:93–100
Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L (2009) Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem 52:6716–6723
Yan Q, Sharma-Kuinkel BK, Deshmukh H, Tsalik EL, Cyr DD, Lucas J, Woods CW, Scott WK, Sempowski GD, Thaden JT, Rude TH, Ahn SH, Fowler VG Jr (2014) Dusp3 and Psme3 are associated with murine susceptibility to Staphylococcus aureus infection and human sepsis. PLoS Pathog 10:e1004149
Yang C, Maiguel DA, Carrier F (2002) Identification of nucleolin and nucleophosmin as genotoxic stress-responsive RNA-binding proteins. Nucleic Acids Res 30:2251–2260
Yano K, Morotomi-Yano K, Wang SY, Uematsu N, Lee KJ, Asaithamby A, Weterings E, Chen DJ (2008) Ku recruits XLF to DNA double-strand breaks. EMBO Rep 9:91–96
Yuvaniyama J, Denu JM, Dixon JE, Saper MA (1996) Crystal structure of the dual specificity protein phosphatase VHR. Science 272:1328–1331
Zhou B, Wang ZX, Zhao Y, Brautigan DL, Zhang ZY (2002) The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J Biol Chem 277:31818–31825
Acknowledgments
This project was supported by FAPESP (Grants # 2008/58264-5 and # 2015/03983-0) and CNPq (Grant # 402230/2016-7) to FLF, head of the Laboratory of Signaling in Biomolecular Systems (LSBS). LCR is a senior postdoctoral fellow from the CAPES-PNPD program at the Institute of Chemistry, University of Sao Paulo. JOF is a PhD student fellow of Fapesp (# 2017/16491-4), and PYFM is a master’s fellow of CNPq, both enrolled at the postgraduation program in Biochemistry and Molecular Biology, Institute of Chemistry, University of Sao Paulo. LFM is a master’s fellow of CAPES at the Biotechnology program, also in University of Sao Paulo. All authors thank BO and JRD for technical assistance in the LSBS laboratory.
Financial Support
Fapesp, Capes, and CNPq.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Monteiro, L.F., Ferruzo, P.Y.M., Russo, L.C., Farias, J.O., Forti, F.L. (2018). DUSP3/VHR: A Druggable Dual Phosphatase for Human Diseases. In: de Tombe, P., Gudermann, T., Jahn, R., Lill, R. (eds) Reviews of Physiology, Biochemistry and Pharmacology 176. Reviews of Physiology, Biochemistry and Pharmacology, vol 176. Springer, Cham. https://doi.org/10.1007/112_2018_12
Download citation
DOI: https://doi.org/10.1007/112_2018_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-14026-7
Online ISBN: 978-3-030-14027-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)